Brains from non-Alzheimer's individuals containing amyloid deposits accelerate Aβ deposition in vivo
Author
dc.contributor.author
Durán Aniotz, Claudia
Author
dc.contributor.author
Morales, Rodrigo
Author
dc.contributor.author
Moreno González, Inés
Author
dc.contributor.author
Hu, Ping Ping
Author
dc.contributor.author
Soto, Claudio
Admission date
dc.date.accessioned
2019-03-18T11:55:05Z
Available date
dc.date.available
2019-03-18T11:55:05Z
Publication date
dc.date.issued
2013
Cita de ítem
dc.identifier.citation
Acta Neuropathologica Communications 2013, 1:76
Identifier
dc.identifier.issn
20515960
Identifier
dc.identifier.other
10.1186/2051-5960-1-76
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/166941
Abstract
dc.description.abstract
Background: One of the main features of Alzheimer’s disease (AD) is the presence of Aβ deposits, which
accumulate in the brain years before the onset of symptoms. We and others have demonstrated that cerebral
Aβ-amyloidosis can be induced in vivo by administration of AD-brain extracts into transgenic mice. However, it is
currently unknown whether amyloid formation can be induced using extracts from individuals harboring Aβ
deposits, but not clinical disease.
Results: In this study we analyzed the amyloid-inducing capability of samples from individuals affected by mild
cognitive impairment (MCI) and Non-Demented persons with Alzheimer’s disease Neuropathology (NDAN). Our
results show that inoculation of transgenic mice with MCI and NDAN brain samples accelerated Aβ pathology in a
similar way as extracts from confirmed AD.
Conclusions: This data demonstrate that the sole presence of Aβ aggregates in a given sample, regardless of the
clinical condition, is capable to accelerate Aβ deposition in vivo. These findings indicate that the amyloid-inducing
activity may be present in the brain of people during pre-symptomatic or a-symptomatic stages of AD.